Medical University of South Carolina - Cancer Center Support Grant

总体情况：摘要 南卡罗来纳医科大学霍林斯癌症中心寻求更新其 通过P30癌症中心支持赠款(CCSG)机制指定国家癌症研究所(NCI)。AS 南卡罗来纳州(SC)领先的学术医疗中心，MUSC负责建立基础、翻译、 临床和以人口为基础的研究计划，以满足该州重要的医疗保健需求。这个 肝细胞癌的使命是通过变革性的研究、患者护理、 预防和公共政策。为了完成这一使命，肝细胞癌领导层建立了一个强大的、多学科的 该中心包括107名癌症科学家。创新、高影响力的研究是由HCC的四项研究推动的 专业：癌症生物学、癌症免疫学、癌症发展治疗学和癌症控制。 高效翻译研究的快速发现和进展得到了五个共享的支持 研究资源：脂质组学、流式细胞术和细胞分选、细胞和分子成像、生物信息库和 组织分析和生物统计学。在本项目期间，该公司成功地利用了CCSG 资金及其NCI指定的癌症中心地位，以利用、扩大和改进该中心的研究 有能力减轻该州的癌症负担。美国癌症委员会支持招募26名新的癌症科学家。 年度直接同行评审的校外研究经费(不包括培训和职业发展 奖金)增加到2160万美元，其中1050万美元来自NCI。肝细胞癌拥有该州最大的临床试验手术 这为进行最现代的癌症试验提供了集中支持。在过去一年中， 肝细胞癌招募了1266名患者参加干预性研究，254名患者参加非干预性研究。肝细胞癌 在克服在招募种族和族裔少数群体方面固有的挑战方面取得重大进展 参与研究。2017年，33%的研究参与者是种族或少数民族，超过 一半居住在被联邦政府指定为医疗服务不足的农村社区。这一进展一直是 二十多年来，由美国癌症委员会领导的循序渐进的外展、社区参与和癌症 教育服务。负责培养下一代多样化和特殊的癌症患者 医生和科学家，该中心开发了该州唯一的全面癌症教育渠道 整个教育过程中的学习者，从高中到职业生涯早期 发展。肝细胞癌致力于提供对最新研究、教育和临床的访问 向整个南卡罗来纳州推进，并且从来没有像现在这样装备好来完成它的使命。由一位新的 中心主任于2017年被任命，肝细胞癌将实施其2023年战略计划，以推进科学 发现，为了解不同人群中的癌症生物学做出了有影响力的贡献，以及 将发现转化为癌症控制、诊断、治疗和公共政策的变革性方法。

OVERALL: SUMMARY The Hollings Cancer Center (HCC) at the Medical University of South Carolina (MUSC) seeks renewal of its National Cancer Institute (NCI) designation via the P30 Cancer Center Support Grant (CCSG) mechanism. As South Carolina's (SC) leading academic medical center, MUSC is charged with building basic, translational, clinical, and population-based research programs that address the state's significant healthcare needs. The mission of the HCC is to reduce the cancer burden in SC through transformative research, patient care, prevention, and public policy. To accomplish this mission, HCC leadership built a robust, multidisciplinary center that includes 107 cancer scientists. Innovative, high-impact research is driven by HCC’s four research programs: Cancer Biology, Cancer Immunology, Developmental Cancer Therapeutics, and Cancer Control. The rapid pace of discovery and movement toward effective translational research is supported by five shared research resources: Lipidomics, Flow Cytometry & Cell Sorting, Cell & Molecular Imaging, Biorepository & Tissue Analysis, and Biostatistics. During the current project period, the HCC successfully leveraged CCSG funding and its NCI-designated cancer center status to harness, expand and improve the center’s research capabilities to decrease the state’s cancer burden. HCC supported recruitment of 26 new cancer scientists. The annual direct peer-reviewed extramural research funding (excluding training and career development awards) increased to $21.6M, with $10.5M from NCI. HCC boasts the state’s largest clinical trials operation that provides centralized support for conducting the most contemporary cancer trials. During the past year, the HCC recruited 1,266 patients to interventional studies and 254 patients to non-interventional studies. HCC made significant progress in overcoming the challenges inherent in recruiting racial and ethnic minorities to participate in research. In 2017, 33% of research participants were racial or ethnic minorities, with more than half residing in rural communities federally designated as medically underserved. This progress has been maintained for over two decades by progressive, HCC-led outreach, community engagement, and cancer education services. With the charge of training the next generation of diverse and exceptional cancer physicians and scientists, the center developed the state’s only comprehensive cancer education pipeline for learners across the entire education continuum, from high school through early professional career development. The HCC is committed to providing access to the latest research, educational, and clinical advances to all of South Carolina, and has never been better equipped to fulfill its mission. Led by a new center director appointed in 2017, the HCC will implement its 2023 strategic plan to advance scientific discovery, make impactful contributions to the understanding of cancer biology in a diverse population, and translate discoveries into transformative approaches to cancer control, diagnosis, treatment, and public policy.